Immunotherapy for colorectal cancer

被引:10
作者
Maxwell-Armstrong, CA
Durrant, LG
Scholefield, JH
机构
[1] Univ Nottingham, Dept Surg, Nottingham NG7 2RD, England
[2] Univ Nottingham, Dept Clin Oncol, Nottingham NG7 2RD, England
关键词
D O I
10.1016/S0002-9610(99)00051-3
中图分类号
R61 [外科手术学];
学科分类号
摘要
BACKGROUND: Advances in molecular biology have enabled specific antigens present on colorectal cells to be characterized, against which immune responses may be generated. This, in combination with our inability to significantly alter survival from this condition, has resurrected an interest in immunotherapy as a potential treatment option. DATA SOURCES: The information contained in this review was obtained following a search of MEDLINE and BIDS (Bath Information Data System), using the key words immunotherapy, colorectal cancer, antibody, anti-idiotype, peptide vaccine, viral vector, and vaccine. In addition, journals related to this field were systematically searched. CONCLUSION: A number of approaches currently constitute immunotherapeutic options for colorectal cancer. A number of treatment modalities are already in phase III studies, although clearly not all will fulfill their initial promise. Surgeons need to be aware of the advances in this rapidly expanding field, and keep an open mind as to their efficacy. Am J Surg. 1999;177:344-348. (C) 1999 by Excerpta Medica, Inc.
引用
收藏
页码:344 / 348
页数:5
相关论文
共 65 条
  • [1] ARNAND JP, 1959, BRIT J SURG, V76, P284
  • [2] Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library
    Begent, RHJ
    Verhaar, MJ
    Chester, KA
    Casey, JL
    Green, AJ
    Napier, MP
    HopeStone, LD
    Cushen, N
    Keep, PA
    Johnson, CJ
    Hawkins, RE
    Hilson, AJW
    Robson, L
    [J]. NATURE MEDICINE, 1996, 2 (09) : 979 - 984
  • [3] Brivio F, 1996, ONCOLOGY, V53, P263
  • [4] Buzzi S., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P397
  • [5] LONG-TERM SURVIVAL FOLLOWING LEVAMISOLE OR PLACEBO ADJUVANT TREATMENT OF COLORECTAL-CANCER - A WESTERN CANCER STUDY-GROUP TRIAL
    CHLEBOWSKI, RT
    NYSTROM, S
    REYNOLDS, R
    WEINER, JM
    BATEMAN, JR
    [J]. ONCOLOGY, 1988, 45 (03) : 141 - 143
  • [6] Ciernik IF, 1996, J IMMUNOL, V156, P2369
  • [7] CONRY RM, 1994, CANCER RES, V54, P1164
  • [8] Phase I trial of an Anti-CD19 deglycosylated ricin A chain immunotoxin in non-Hodgkin's lymphoma: Effect of an intensive schedule of administration
    Conry, RM
    Khazaeli, MB
    Saleh, MN
    Ghetie, V
    Vitetta, ES
    Liu, TP
    LoBuglio, AF
    [J]. JOURNAL OF IMMUNOTHERAPY, 1995, 18 (04) : 231 - 241
  • [9] CLINICAL OUTCOME OF COLORECTAL-CANCER PATIENTS TREATED WITH HUMAN MONOCLONAL ANTIIDIOTYPIC ANTIBODY
    DENTON, GWL
    DURRANT, LG
    HARDCASTLE, JD
    AUSTIN, EB
    SEWELL, HF
    ROBINS, RA
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1994, 57 (01) : 10 - 14
  • [10] FAGERBERG J, 1995, CANCER RES, V55, P1824